Disclosures for "Impact of Baseline Polyneuropathy Severity on Vutrisiran Treatment Response in the Phase 3 HELIOS-A Study"
-
The institution of Dr. Quan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam. The institution of Dr. Quan has received research support from Alnylam. The institution of Dr. Quan has received research support from Pfizer. The institution of Dr. Quan has received research support from Cytokinetics. The institution of Dr. Quan has received research support from Argenx. The institution of Dr. Quan has received research support from Momenta. The institution of Dr. Quan has received research support from Ionis. The institution of Dr. Quan has received research support from Alexion. The institution of Dr. Quan has received research support from VielaBio. The institution of Dr. Quan has received research support from Apellis. The institution of Dr. Quan has received research support from Avidity. Dr. Quan has received publishing royalties from a publication relating to health care. Dr. Quan has received publishing royalties from a publication relating to health care. Dr. Quan has a non-compensated relationship as a Board Member/President with AANEM that is relevant to AAN interests or activities.
-
Dr. Luigetti has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Luigetti has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sobi. Dr. Luigetti has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam.
-
John L. Berk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam Pharmaceuticals. John L. Berk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ionis Pharmaceuticals. John L. Berk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astra Zeneca/IONIS. John L. Berk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eidos/BridgBio. John L. Berk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Intellia Therapeutics. John L. Berk has received research support from Alnylam . John L. Berk has received research support from Ionis. John L. Berk has received research support from Eidos/Bridgbio.
-
Dr. Conceicao has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam. Dr. Conceicao has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Conceicao has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam. Dr. Conceicao has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SOBI. The institution of Dr. Conceicao has received research support from Pfizer.
-
The institution of Dr. Misumi has received research support from Alnylam pharmaceuticals. The institution of Dr. Misumi has received research support from Pfizer Inc.
-
Dr. Chao has nothing to disclose.
-
Dr. Bender has received personal compensation for serving as an employee of Alnylam Pharmaceuticals, Inc.. Dr. Bender has received personal compensation for serving as an employee of Boehringer Ingelheim Pharmaceuticals, Inc.. Dr. Bender has stock in Alnylam Pharmaceuticals, Inc..
-
Emre Aldinc has received personal compensation for serving as an employee of Alnylam Pharmaceuticals. Emre Aldinc has stock in Alnylam Pharmaceuticals.
-
John Vest has received personal compensation for serving as an employee of Alnylam Pharmaceuticals. John Vest has received stock or an ownership interest from Alnylam Pharmaceuticals. John Vest has received intellectual property interests from a discovery or technology relating to health care.
-
David D. Adams has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for ALNYLAM. David D. Adams has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer.